almagate has been researched along with Macular Degeneration in 195 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 127 (65.13) | 29.6817 |
| 2010's | 67 (34.36) | 24.3611 |
| 2020's | 1 (0.51) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, H; Nakamura, S | 1 |
| Cannon, E | 1 |
| Castanotto, D; Stein, CA | 1 |
| Buyse, M; Coart, E; Punt, CJ; Quinaux, E; Saad, ED; Squifflet, P | 1 |
| Battaglia Parodi, M; Brue, C; Cappello, E; Di Bartolo, E; Furino, C; Giuffrida, S; Imparato, M; Reibaldi, M | 1 |
| Chilov, M; Nguyen, CL; Oh, LJ; Wei, J; Wong, E | 1 |
| Levy, M; Yan, AC | 1 |
| Hawkins, BS; Krzystolik, MG; Lindsley, K; Solomon, SD; Vedula, SS | 2 |
| de Graeff, PA; Haaijer-Ruskamp, FM; Mol, PG; Piening, S; Straus, SM | 1 |
| Lin, JS; Lü, YH; Wang, QZ; Yang, HY; Zhu, Y | 1 |
| Choovuthayakorn, J; Ittipunkul, N; Kunavisarut, P; Pathanapitoon, K; Patikulsila, D; Saenpen, N; Watanachai, N | 1 |
| Chong, NV; Morjaria, R | 1 |
| DeCastro Molina, JA; George, PP; Heng, BH | 1 |
| Alimanovic, E; Cekic, S; Jaksic, V; Kasumovic, SS; Mavija, M; Stamenkovic, M | 1 |
| Amato, R; Biagi, C; Buccellato, E; Conti, V; Covezzoli, A; Donati, M; Melis, M; Montanaro, N; Motola, D; Pazzi, L; Vaccheri, A; Venegoni, M | 1 |
| Kim, IK; Yonekawa, Y | 1 |
| Kobayashi, M; Manabe, S; Ono, A; Shiraga, F; Shiragami, C; Yamashita, A | 1 |
| Aslankara, H; Kaynak, S; Koçak, N; Selım, A | 1 |
| Losada, M; Manresa, N; Mulero, J; Zafrilla, P | 1 |
| Hernandez, FJ; Hernandez, LI; Machado, I; Schafer, T | 1 |
| Kanwar, JR; Kanwar, R; Sriramoju, B; Veedu, RN | 1 |
| Fujino, Y; Kawashima, H; Nishida, J; Nomura, Y; Takahashi, H; Yanagi, Y | 1 |
| Avitabile, T; Bonfiglio, V; Casuccio, A; Cennamo, G; Cillino, S; Furino, C; Longo, A; Pani, L; Parisi, G; Parravano, M; Reibaldi, M; Russo, A; Uva, MG; Xoxi, E | 1 |
| Feucht, N; Huebner, M; Lohmann, C; Maier, M | 1 |
| Bautista-Paloma, J; Flores-Moreno, S | 1 |
| Adamis, AP; Buggage, R; Cunningham, E; Goldbaum, M; Guyer, D; Katz, B; Masonson, H; Patel, M; Singerman, LJ | 1 |
| Chang, LK; Chiang, A; Sarraf, D; Yu, F | 1 |
| Atmani, K; Coscas, F; Coscas, G; Soubrane, G | 1 |
| Qureshi, SH; van Wijngaarden, P | 1 |
| Beresniak, A; Bisot-Locard, S; Bremond-Gignac, D; Citterio, T; Cohen, SY; Mimoun, G; Quentel, G | 1 |
| Tano, Y | 1 |
| Cohen, SY; Coscas, G; Creuzot-Garcher, C; Devin, F; Gaudric, A; Korobelnik, JF; Mauget-Faysse, M; Sahel, JA; Soubrane, G; Souied, E; Tadayoni, R; Weber, M | 1 |
| Adelman, RA; Lu, F | 1 |
| Brown, GC; Brown, MM; Ho, AC; Huang, SS; Ip, MS; Recchia, FM; Scott, IU | 1 |
| Gutfleisch, M; Heimes, B; Lommatzsch, AP; Pauleikhoff, D; Spital, G; Zeimer, M | 1 |
| Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
| Bhisitkul, RB; Fung, AE | 1 |
| Bakri, SJ; Depperschmidt, E; Fung, AE; Gibson, A; Palanki, R | 1 |
| Garcia-Layana, A; Giraldez, J; Hernandez-Pastor, LJ; Ortega, A | 2 |
| Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Spital, G; Zeimer, M | 1 |
| Hughes, MS; Sang, DN; Shah, GK | 1 |
| Kurz-Levin, M; Michels, S | 1 |
| Menon, G; Walters, G | 1 |
| Jeganathan, VS; Verma, N | 1 |
| Barakat, MR; Kaiser, PK | 1 |
| Ciulla, TA; Rosenfeld, PJ | 1 |
| Castellarin, AA; Driscoll, S; Halperin, LS; Hassan, TS; Klein, KS; Prenner, JL; Roth, D; Walsh, MK | 1 |
| Esaka, E; Nagaoka, M; Nakane, M; Oishi, M; Tahara, M | 1 |
| Klettner, A; Roider, J | 1 |
| Csaky, K; Do, DV | 1 |
| Da Rocha Gomes, S; Dausse, E; Toulmé, JJ | 1 |
| Barbosa, A; Beatty, S; Campos, A; Eldem, B; Faria, R; Feucht, N; Grisanti, S; Hykin, P; Kadayifçilar, S; Kolar, P; Maestroni, L; Olea, JL; Rito, L; Saeed, A; Silva, R; Sivaprasad, S; Staurenghi, G | 1 |
| Bressler, SB | 1 |
| Thelen, U | 1 |
| Bass, EB; Bressler, NM; Cassard, SD; Gower, EW; Schein, OD | 1 |
| Nelson, M | 1 |
| Goss, TF; Weber, PA; Wirostko, BM; Xu, X; Zlateva, G | 1 |
| Wiwanitkit, V | 1 |
| Campbell, S; Friberg, TR; Goldbaum, M; Patel, S; Tolentino, M; Weber, P | 1 |
| Chen, FK; Ikeji, F; Keane, PA; Ouyang, Y; Patel, PJ; Sadda, SR; Tufail, A; Walsh, AC | 1 |
| Dietzel, M; Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Spital, G | 1 |
| Bolz, M; Mitsch, C; Pollreisz, A; Schmidt-Erfurth, U | 1 |
| Cennamo, G; Cesarano, I; D'Amico, G; De Crecchio, G; Finelli, M; Forte, R | 1 |
| Chrapek, O; Dusek, L; Jarkovský, J; Kandrnal, V; Pitrová, S; Rehák, J | 1 |
| Ernest, J; Pitrová, S | 1 |
| Pracharová, Z; Rehák, J; Simicák, J; Sín, M | 1 |
| Hovorka, M | 1 |
| Frenkel, MP; Frenkel, RE; Haji, SA | 1 |
| Buyse, M | 1 |
| Joussen, AM; Wong, D | 1 |
| Babish, JD; Brechner, RJ; Caplan, S; Rosenfeld, PJ | 1 |
| Kirchhof, B; Pauleikhoff, D | 1 |
| Arcidiacono, B; Costagliola, C; Morescalchi, F; Parmeggiani, F; Semeraro, F | 1 |
| Kühn, T | 1 |
| Acquah, K; Day, S; Grossman, DS; Lee, PP; Mruthyunjaya, P; Sloan, FA | 1 |
| Bird, A; Dietzel, M; Gutfleisch, M; Heimes, B; Lommatzsch, A; Pauleikhoff, D; Schumacher, M | 1 |
| De Jong-Hesse, Y; Hendrikse, F; La Heij, EC; Ringens, PJ; Schouten, JS; van der Reis, MI | 1 |
| Albini, TA; Berrocal, AM; Davis, JL; Dubovy, SR; Flynn, HW; Kovach, JL; Lalwani, GA; Lee, WH; Moshfeghi, AA; Murray, TG; Puliafito, CA; Rosenfeld, PJ; Schwartz, SG; Smiddy, WE | 1 |
| Choi, DY; Gorin, MB; Hubschman, JP; McCannel, CA; McCannel, TA; Ortube, MC; Sarraf, D | 1 |
| Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
| Basile, AS; Hutmacher, M; Kowalski, K; Masayo, O; Nakane, M; Nickens, D; Nielsen, J; Whitfield, L | 1 |
| Aihara, Y; Fukuda, T; Hashimoto, H; Yanagi, Y | 1 |
| Huic, M; Zechmeister-Koss, I | 1 |
| Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF | 1 |
| Heussen, FM; Keane, PA; Mokwa, N; Ouyang, Y; Patel, PJ; Sadda, SR; Tufail, A; Walsh, AC | 1 |
| Athanasakis, K; Fragoulakis, V; Kyriopoulos, J; Maniadakis, N; Masaoutis, P; Tsiantou, V | 1 |
| Kang, KN; Lee, YS | 1 |
| Andréasson, S; Bruun, A; Ghosh, F; Lövestam Adrian, M; Myers, AC; Ponjavic, V | 1 |
| Chong, V | 1 |
| Coco, RM; Fernández Muñoz, M; Hernandez, AG; Sanabria, MR | 1 |
| Dombi, T; Kwok, KK; Sultan, MB | 1 |
| Buggage, R; Chakravarthy, U; Kwok, K; Staurenghi, G; Tressler, CS | 1 |
| Chrapek, O; Jakubcová, M; Pracharová, Z; Rehák, J; Simicák, J; Sin, M | 1 |
| Chrapek, O; Dubska, Z; Dusova, J; Kandrnal, V; Kolar, P; Pitrova, S; Rehak, J; Rencova, E; Rozsival, P; Studnicka, J | 1 |
| Adamis, AP; Cunningham, ET; Feinsod, M; Gragoudas, ES; Guyer, DR | 1 |
| Fine, SL; Kirkpatrick, P; Martin, DF | 1 |
| Coster, DJ; van Wijngaarden, P; Williams, KA | 1 |
| Schachat, AP | 1 |
| Morrow, T | 1 |
| Blaise, P; Foidart, JM; Rakic, JM | 1 |
| Moshfeghi, AA; Puliafito, CA | 1 |
| Adamis, AP; Ng, EW | 2 |
| Doggrell, SA | 1 |
| Keating, GM; Siddiqui, MA | 1 |
| Arias Barquet, L | 1 |
| Hansen, MH; Mortensen, KK; Sjølie, AK | 1 |
| Haamann, PH; la Cour, M; Larsen, M; Lund-Andersen, H; Sander, B; Villumsen, JE | 1 |
| Gryziewicz, L | 1 |
| Pauleikhoff, D | 1 |
| Canny, MD; De Erkenez, A; Jucker, F; Krilleke, D; Lee, JH; Ng, YS; Pardi, A; Shima, DT | 1 |
| Blinder, KJ; Hariprasad, SM; Shah, GK | 1 |
| Uwaydat, SH; Wiggins, MN | 1 |
| Spaide, R | 1 |
| Mones, J | 1 |
| Fraunfelder, FW | 1 |
| Hussar, DA | 1 |
| Kourlas, H; Schiller, DS | 1 |
| Baumal, CR; Duker, JS; Reichel, E; Rogers, AH; Schuman, S | 1 |
| Spires, RA | 1 |
| Apte, RS; Blinder, KJ; Dhalla, MS; Hariprasad, SM; Tewari, A | 1 |
| Adamis, AP; Cunningham, ET; D'Amico, DJ; Guyer, DR; Katz, B; Masonson, HN; Patel, M | 1 |
| Wang, B; Zhou, B | 1 |
| Arroyo, JG | 1 |
| Michels, S; Rosenfeld, PJ; Schmidt-Erfurth, U | 1 |
| Sears, JE; Singh, RP | 1 |
| Adamis, AP; Chakravarthy, U; Cunningham, ET; Goldbaum, M; Guyer, DR; Katz, B; Patel, M | 1 |
| Menéndez de Lucas, JA; Morcillo Laiz, R | 1 |
| Levin, GM | 1 |
| Bandello, F; Chakravarthy, U; Chong, V; Creuzot-Garcher, C; Dimitrakos, SA; Korobelnik, JF; Larsen, M; Monés, J; Pauleikhoff, D; Pournaras, CJ; Soubrane, G; Staurenghi, G; Virgili, G; Wolf, S | 1 |
| D'Amico, DJ; Vavvas, D | 1 |
| Kaiser, PK | 2 |
| Fekrat, S; Williams, AJ | 1 |
| Bhisitkul, RB; Rutar, T | 1 |
| Goldbaum, M; Katz, B | 1 |
| Del Priore, LV; Shah, AR | 1 |
| Lin, RC; Rosenfeld, PJ | 1 |
| Bailey, C; Imrie, FR | 1 |
| Behar-Cohen, F; Berdugo, M; Sennlaub, F | 1 |
| Brown, GC; Brown, HC; Brown, MM; Kindermann, S; Sharma, S | 1 |
| Bienias, W; Nowak, JZ | 1 |
| Guyatt, G; Heels-Ansdell, D; Kelly, S; Mills, E | 1 |
| Ulińska, M | 1 |
| Clegg, AJ; Colquitt, J; Jones, J; Takeda, AL | 1 |
| Adamis, AP; Apte, RS; Masonson, H; Modi, M; Patel, M; Whitfield, L | 1 |
| Frenkel, MP; Frenkel, RE; Mani, L; Toler, AR | 1 |
| Joussen, AM | 1 |
| Covell, CA; Graziano, JA; Rich, D; Tobin, KA | 1 |
| Leys, A; Patel, M; Shah, SN; Zlateva, G | 1 |
| Holz, FG | 1 |
| Brubaker, JW; Collins, AT; Joeres, S; Kaplowitz, K; Romano, PW; Sadda, SR; Updike, PG; Walsh, AC | 1 |
| Liew, G; Mitchell, P; Wong, TY | 1 |
| Olsen, TW | 1 |
| Teper, SJ; Wylegała, E | 1 |
| Goldstein, M; Leibovitch, I; Loewenstein, A; Waisbourd, M | 1 |
| Vinores, SA | 1 |
| Dayani, PN; Holekamp, NM; Siddiqi, OK | 1 |
| Brand, CS; Kelly, S; Maciver, FM; Roskell, N; Wolowacz, SE | 1 |
| Hassan, TS; Quiram, PA; Williams, GA | 1 |
| Chang, LK; Flaxel, CJ; Lauer, AK; Sarraf, D | 1 |
| Bornfeld, N; Jurklies, B; Lipski, A | 1 |
| Novack, GD | 1 |
| Avery, RL | 1 |
| Rosenfeld, PJ | 1 |
| Kompella, UB | 1 |
| Adán, A; Casaroli-Marano, RP | 1 |
| Earnshaw, SR; Moride, Y; Rochon, S | 1 |
| Feucht, N; Kotliar, KE; Lanzl, IM; Lohmann, CP; Maier, M | 1 |
| Calvo-González, C; Donate-López, J; Fernández-Pérez, C; García-Feijoó, J; Garcia-Sánchez, J; Leila, M; Reche-Frutos, J | 1 |
| Ishida, S | 1 |
| Pountney, D | 1 |
| Apte, RS | 1 |
| Eter, N; Meyer, CH | 1 |
| Eter, N; Helb, HM; Meyer, CH | 1 |
| Meyer, CH | 1 |
| Heimann, H; Meyer, CH; Ziemssen, F | 1 |
| Parier, V; Soubrane, G | 1 |
| Cohen, AF; Dubois, EA; van Bronswijk, H; van Meurs, JC | 1 |
| Maiti, A; Natarajan, S; Uparkar, M | 1 |
| Dadgostar, H; Waheed, N | 1 |
| Harding, SP; Heimann, H; Kumar, N; Lenfestey, PM; Mahmood, S; Murjaneh, S | 1 |
| Krzystolik, MG; Vedula, SS | 1 |
| Clegg, AJ; Colquitt, JL; Jones, J; Price, A; Takeda, A; Tan, SC | 1 |
| Gajdzik-Gajdecka, U; Smuzyńska, M; Trzciakowski, K; Wykrota, H | 1 |
64 review(s) available for almagate and Macular Degeneration
| Article | Year |
|---|---|
[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Drug Development; Humans; Macular Degeneration; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2021 |
Managed care opportunities and approaches to supporting appropriate selection of treatment for sight preservation.
Topics: Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost-Benefit Analysis; Humans; Intravitreal Injections; Macular Degeneration; Managed Care Programs; Medicare; Off-Label Use; Pharmaceutical Services; Professional Role; Quality-Adjusted Life Years; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; United States; Vascular Endothelial Growth Factor A; Vision Disorders | 2019 |
FDA-Approved Oligonucleotide Therapies in 2017.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Cytomegalovirus Retinitis; Drug Approval; Hepatic Veno-Occlusive Disease; Humans; Hypercholesterolemia; Macular Degeneration; Morpholinos; Muscular Atrophy, Spinal; Muscular Dystrophy, Duchenne; Oligonucleotides; Oligonucleotides, Antisense; Polydeoxyribonucleotides; Thionucleotides | 2017 |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A; Visual Acuity | 2018 |
Aptamer-Mediated Delivery and Cell-Targeting Aptamers: Room for Improvement.
Topics: Aptamers, Nucleotide; Biological Transport; Clinical Trials as Topic; Cytosol; Endosomes; Gene Transfer Techniques; Genetic Therapy; Humans; Macular Degeneration; Oligonucleotides, Antisense; RNA, Small Interfering; SELEX Aptamer Technique; Structure-Activity Relationship | 2018 |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Middle Aged; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity | 2019 |
[Recent progress of the aptamer-based antiviral drugs].
Topics: Antiviral Agents; Aptamers, Nucleotide; Genome, Viral; Hepacivirus; HIV; HIV Reverse Transcriptase; Humans; Macular Degeneration; Neoplasms; Oligodeoxyribonucleotides; RNA, Small Interfering; SELEX Aptamer Technique; Viral Envelope Proteins; Virus Replication | 2013 |
Pharmacokinetic evaluation of pegaptanib octasodium for the treatment of diabetic edema.
Topics: Animals; Aptamers, Nucleotide; Cardiovascular Diseases; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Risk Factors; Vascular Endothelial Growth Factor A; Vision Disorders | 2014 |
The methodological quality of systematic reviews comparing intravitreal bevacizumab and alternates for neovascular age related macular degeneration: A systematic review of reviews.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Humans; Intravitreal Injections; Macular Degeneration; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2014 |
Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Intravitreal Injections; Macular Degeneration; Middle Aged; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity | 2014 |
Therapeutic modalities of exudative age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Humans; Lenses, Intraocular; Macular Degeneration; Radiation, Ionizing; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2014 |
Clinical characteristics and current treatment of age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Drug Therapy, Combination; Humans; Light Coagulation; Macular Degeneration; Middle Aged; Photochemotherapy; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Risk Factors; Vascular Endothelial Growth Factor A | 2014 |
Aptamers overview: selection, features and applications.
Topics: Aptamers, Nucleotide; Biological Assay; Drug Delivery Systems; Drug Discovery; Food Technology; Humans; Macular Degeneration; Molecular Targeted Therapy; Reagent Kits, Diagnostic; SELEX Aptamer Technique; Small Molecule Libraries; Staining and Labeling | 2015 |
Aptamer-targeted oligonucleotide theranostics: a smarter approach for brain delivery and the treatment of neurological diseases.
Topics: Alzheimer Disease; Aptamers, Nucleotide; Aptamers, Peptide; Blood-Brain Barrier; Brain Neoplasms; Drug Delivery Systems; Humans; Macular Degeneration; Molecular Targeted Therapy; Multiple Sclerosis; Myasthenia Gravis; Parkinson Disease; SELEX Aptamer Technique; Stroke; Theranostic Nanomedicine | 2015 |
Inhibitors of vascular endothelial growth factor (VEGF) in the management of neovascular age-related macular degeneration: a review of current practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Macular Degeneration; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A | 2008 |
Anti-vascular endothelial growth factor pharmacotherapy for age-related macular degeneration: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy; Humans; Macular Degeneration; Ranibizumab; Technology Assessment, Biomedical; Treatment Outcome; United States; Vascular Endothelial Growth Factor A | 2008 |
Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2009 |
[Age-related macular degeneration (AMD)].
Topics: Adult; Age Factors; Aged; Antioxidants; Aptamers, Nucleotide; Diet; Fluorescein Angiography; Fundus Oculi; Genetic Predisposition to Disease; Humans; Macular Degeneration; Middle Aged; Photochemotherapy; Polymorphism, Genetic; Prevalence; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Smoking; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Zinc | 2009 |
Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Injections; Macular Degeneration; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
VEGF inhibitors for the treatment of neovascular age-related macular degeneration.
Topics: Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Approval; Humans; Macular Degeneration; Ranibizumab; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2009 |
Treating age-related macular degeneration - interaction of VEGF-antagonists with their target.
Topics: Age Factors; Amino Acid Sequence; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Molecular Sequence Data; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; RNA, Small Interfering; Vascular Endothelial Growth Factors | 2009 |
Aptamers: a new class of oligonucleotides in the drug discovery pipeline?
Topics: Animals; Aptamers, Nucleotide; Drug Discovery; High-Throughput Screening Assays; Humans; Macular Degeneration; Nucleic Acid Conformation; SELEX Aptamer Technique; Small Molecule Libraries; Structure-Activity Relationship; Vascular Endothelial Growth Factor A | 2009 |
Introduction: Understanding the role of angiogenesis and antiangiogenic agents in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A | 2009 |
Systemic adverse drug reactions secondary to anti-VEGF intravitreal injection in patients with neovascular age-related macular degeneration.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Intravitreal Injections; Ligands; Macular Degeneration; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
A systematic review of the adverse events of intravitreal anti-vascular endothelial growth factor injections.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A | 2011 |
Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Retreatment; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
RNA aptamers: a review of recent trends and applications.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Cooperative Behavior; Humans; Inflammation; Ligands; Macular Degeneration; SELEX Aptamer Technique; Social Support; Vascular Endothelial Growth Factor A | 2013 |
Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Vascular Endothelial Growth Factor A | 2012 |
Inhibitors of ocular neovascularization: promises and potential problems.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Injections; Macular Degeneration; Oligonucleotides; Ranibizumab; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Humans; Macular Degeneration; Retinal Neovascularization; Vascular Endothelial Growth Factor A; Vitreous Body | 2005 |
Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Neovascularization, Pathologic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib: the first antiangiogenic agent approved for neovascular macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Neovascularization, Pathologic; Vascular Endothelial Growth Factor A | 2005 |
Pegaptanib: in exudative age-related macular degeneration.
Topics: Animals; Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Randomized Controlled Trials as Topic; Visual Acuity; Vitreous Body | 2005 |
Regulatory aspects of drug approval for macular degeneration.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Drug Approval; Drugs, Investigational; Humans; Macular Degeneration; Porphyrins; Treatment Outcome; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A; Verteporfin | 2005 |
neovascular age-related macular degeneration: Natural History and Treatment Outcomes.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Fluorescein Angiography; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Prognosis; Treatment Outcome; Visual Acuity | 2005 |
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: a review.
Topics: Animals; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Treatment Outcome | 2006 |
How you can help when older eyes fail.
Topics: Age Distribution; Aged; Aptamers, Nucleotide; Causality; Disease Progression; Humans; Laser Coagulation; Macular Degeneration; Middle Aged; Nurse's Role; Nursing Assessment; Patient Education as Topic; Photochemotherapy; Referral and Consultation; Risk Assessment; United States; Visual Acuity | 2006 |
Pegaptanib for the treatment of age-related macular degeneration.
Topics: Aptamers, Nucleotide; Drug Administration Schedule; Drug Costs; Humans; Macular Degeneration; Models, Animal; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2006 |
Promising new treatments for neovascular age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Capillary Permeability; Cholestanols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Double-Blind Method; Drug Design; Drugs, Investigational; Eye Proteins; Humans; Injections; Lactates; Macular Degeneration; Models, Animal; Multicenter Studies as Topic; Neovascularization, Pathologic; Nerve Growth Factors; Pigment Epithelium of Eye; Protein Isoforms; Randomized Controlled Trials as Topic; RNA Interference; RNA, Small Interfering; Serpins; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Vitreous Body | 2006 |
Pegaptanib (Macugen): treating neovascular age-related macular degeneration and current role in clinical practice.
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Retinal Neovascularization; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Expanding treatment options in age-related macular degeneration.
Topics: Aptamers, Nucleotide; Drug Therapy, Combination; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Macugen (pegaptanib sodium), a novel ocular therapeutic that targets vascular endothelial growth factor (VEGF).
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Retinal Neovascularization; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases.
Topics: Aptamers, Nucleotide; Clinical Trials as Topic; Diabetes Complications; Humans; Macular Degeneration; Macular Edema; Retinal Degeneration; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Blindness; Choroidal Neovascularization; Disease Progression; Exudates and Transudates; Humans; Macula Lutea; Macular Degeneration; Photochemotherapy; Pregnadienediols; Randomized Controlled Trials as Topic; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Antiangiogenic therapy in neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Haplorhini; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Porphyrins; Prognosis; Ranibizumab; Risk Assessment; Treatment Outcome; Verteporfin; Visual Acuity | 2007 |
[Age-related macular degeneration (AMD): etiopathogenesis and therapeutic strategies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Bevacizumab; Humans; Lipofuscin; Macular Degeneration; Neovascularization, Pathologic; Photochemotherapy; Pregnadienediols; Ranibizumab; Retinal Drusen; Triamcinolone Acetonide | 2007 |
[Pegaptanib sodium in treatment of wet AMD].
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Retinal Neovascularization; Vascular Endothelial Growth Factor A | 2006 |
Pegaptanib and ranibizumab for neovascular age-related macular degeneration: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Infant, Newborn; Macular Degeneration; Neovascularization, Pathologic; Ranibizumab; Retinal Diseases; Retinopathy of Prematurity; Vascular Diseases | 2007 |
[VEGF in age-related macular degeneration. Part II. VEGF inhibitors use in age-related macular degeneration treatment].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Retina; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Topics: Aging; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Delivery Systems; Humans; Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Pegaptanib in the treatment of wet, age-related macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Macular Degeneration; Vascular Endothelial Growth Factor A | 2006 |
A view on new drugs for macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drugs, Investigational; Humans; Macular Degeneration; Ranibizumab | 2007 |
Pharmacotherapy for the treatment of choroidal neovascularization due to age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Laser Coagulation; Macular Degeneration; Porphyrins; Prevalence; Ranibizumab; Verteporfin | 2008 |
Pegaptanib sodium for the treatment of age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Protein Isoforms; Vascular Endothelial Growth Factor A | 2008 |
[Monitoring of AMD patients on anti-vascular endothelial growth factor (VEGF) treatment. Practical notes on functional and anatomical examination parameters from drug approval studies, specialist information and case series].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blindness; Choroidal Neovascularization; Clinical Trials, Phase III as Topic; Fluorescein Angiography; Follow-Up Studies; Humans; Injections; Macular Degeneration; Meta-Analysis as Topic; Monitoring, Physiologic; Multicenter Studies as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Retrospective Studies; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Verteporfin; Vision Tests; Visual Acuity; Vitreous Body | 2008 |
[Intravitreal injection. Monitoring to avoid postoperative complications].
Topics: Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cataract; Clinical Trials, Phase III as Topic; Endophthalmitis; Eye Hemorrhage; Female; Fetus; Hallucinations; Humans; Injections; Intraocular Pressure; Macular Degeneration; Mice; Paracentesis; Postoperative Complications; Pregnancy; Rabbits; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Detachment; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
[Age-related macular degeneration].
Topics: Age Factors; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Dietary Supplements; Fluorescein Angiography; Humans; Laser Coagulation; Macular Degeneration; Middle Aged; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Verteporfin | 2008 |
[New drugs; pegaptanib and ranibizumab].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Disease Progression; Humans; Macular Degeneration; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2008 |
The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Clinical Trials, Phase III as Topic; Corneal Neovascularization; Dose-Response Relationship, Drug; Female; Humans; Macular Degeneration; Male; Practice Guidelines as Topic; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2008 |
Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Humans; Macular Degeneration; Middle Aged; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2008 |
Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Contrast Sensitivity; Cost-Benefit Analysis; Drug Costs; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Visual Acuity | 2008 |
21 trial(s) available for almagate and Macular Degeneration
| Article | Year |
|---|---|
The Additional Value of an E-Mail to Inform Healthcare Professionals of a Drug Safety Issue: A Randomized Controlled Trial in the Netherlands.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aptamers, Nucleotide; Attitude of Health Personnel; Communication; Electronic Mail; Female; Humans; Macular Degeneration; Male; Middle Aged; Netherlands; Ophthalmology; Physicians | 2013 |
Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Intraocular Pressure; Macular Degeneration; Male; Tonometry, Ocular; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
[Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration].
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Injections; Macular Degeneration; Male; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
[Treatment of vascularised serous pigment epithelium detachment in AMD - observations after changing the intravitreal agent due to lack of response].
Topics: Aged; Aptamers, Nucleotide; Dose-Response Relationship, Drug; Female; Humans; Macular Degeneration; Male; Retinal Detachment; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL study.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Cornea; Female; Humans; Macular Degeneration; Male; Middle Aged; Prospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration | 2010 |
Effects of retinal morphology on contrast sensitivity and reading ability in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Contrast Sensitivity; Cross-Sectional Studies; Double-Blind Method; Female; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Reading; Retina; Subretinal Fluid; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
[Long-term efficacy and safety profile of pegaptanib sodium for age-related macular degeneration with choroidal neovascularization--evaluation of extended phase II clinical trial].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Population pharmacokinetics of pegaptanib in patients with neovascular, age-related macular degeneration.
Topics: Aged; Aptamers, Nucleotide; Area Under Curve; Cohort Studies; Female; Humans; Kidney Function Tests; Macular Degeneration; Male; Renal Insufficiency; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
Assessment of differential pharmacodynamic effects using optical coherence tomography in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Retinal pigment epithelium tears in age-related macular degeneration treated with antiangiogenic drugs: a controlled study with long follow-up.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Retinal Perforations; Retinal Pigment Epithelium; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2012 |
A retrospective, pooled data analysis of the safety of pegaptanib sodium in the treatment of age-related macular degeneration in subjects with or without diabetes mellitus.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Cross-Over Studies; Diabetes Mellitus; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Macular Degeneration; Retrospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Treating early choroidal neovascularisation with pegaptanib sodium in patients with neovascular age-related macular degeneration: findings of the PERSPECTIVES study.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Early Diagnosis; Humans; Macular Degeneration; Middle Aged | 2012 |
Pegaptanib for neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Prospective Studies; Radiography; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2004 |
[Treatment of neovascular age-related macular degeneration with intravitreal vascular endothelial growth factor inhibitor--secondary publication].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Oligonucleotides; Photochemotherapy; Treatment Outcome; Vascular Endothelial Growth Factors; Visual Acuity; Vitreous Body | 2005 |
Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Double-Blind Method; Female; Fluorescein Angiography; Humans; Indocyanine Green; Injections; Macular Degeneration; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2006 |
A randomized trial of Pegaptanib sodium for age-related macular degeneration used an innovative design to explore disease-modifying effects.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Drug Administration Schedule; Humans; Injections; Macular Degeneration; Middle Aged; Prospective Studies; Research Design; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Pressure; Choroidal Neovascularization; Double-Blind Method; Female; Half-Life; Humans; Immunoglobulin G; Immunoglobulin M; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Prospective Studies; Proteinuria; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
Quality of life in patients with age-related macular degeneration: results from the VISION study.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Middle Aged; Quality of Life; Sickness Impact Profile; Visual Acuity | 2008 |
Combined Pegaptanib sodium (Macugen) and photodynamic therapy in predominantly classic juxtafoveal choroidal neovascularisation in age related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Combined Modality Therapy; Female; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Prospective Studies; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2008 |
[Pegaptanib sodium in treatment of choroidal neovascularization secondary to age-related macular degeneration. One year results].
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Female; Humans; Macular Degeneration; Male; Prospective Studies; Treatment Outcome | 2007 |
110 other study(ies) available for almagate and Macular Degeneration
| Article | Year |
|---|---|
The impact of data errors on the outcome of randomized clinical trials.
Topics: Antineoplastic Agents, Immunological; Aptamers, Nucleotide; Cetuximab; Colorectal Neoplasms; Data Accuracy; Data Interpretation, Statistical; Endpoint Determination; Humans; Macular Degeneration; Observer Variation; Randomized Controlled Trials as Topic; Treatment Outcome | 2017 |
Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fundus Oculi; Humans; Intravitreal Injections; Macular Degeneration; Male; Retrospective Studies; Thromboembolism; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2018 |
The use of intravitreal anti-vascular endothelial growth factor injection and its complications in Chiang Mai University Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Child; Child, Preschool; Diabetic Retinopathy; Female; Hospitals, University; Humans; Infant; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Thailand; Vascular Endothelial Growth Factor A; Young Adult | 2013 |
Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions.
Topics: Adverse Drug Reaction Reporting Systems; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; World Health Organization | 2014 |
Effect of switching therapy to pegaptanib in eyes with the persistent cases of exudative age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Combined Modality Therapy; Drug Substitution; Exudates and Transudates; Female; Humans; Intravitreal Injections; Macular Degeneration; Macular Edema; Male; Middle Aged; Photochemotherapy; Prospective Studies; Radiography; Ranibizumab; Retina; Retinal Detachment; Tomography, Optical Coherence; Treatment Failure; Visual Acuity | 2014 |
Comparative study of photodynamic therapy monotherapy versus triple management in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Combined Modality Therapy; Female; Glucocorticoids; Humans; Intravitreal Injections; Macular Degeneration; Male; Photochemotherapy; Treatment Outcome; Triamcinolone; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |
Influence of anti-VEGF about cardiovascular biomarkers in age related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Atherosclerosis; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Female; Fibrinogen; Homocysteine; Humans; Lipids; Macular Degeneration; Male; Middle Aged; Ranibizumab; Risk Factors; Vascular Endothelial Growth Factor A; Wet Macular Degeneration | 2015 |
Vascular Endothelial Growth Factor (VEGF) Concentration Is Underestimated by Enzyme-Linked Immunosorbent Assay in the Presence of Anti-VEGF Drugs.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Chemokine CCL2; Enzyme-Linked Immunosorbent Assay; Half-Life; Humans; Intravitreal Injections; Macular Degeneration; Ranibizumab; Reagent Kits, Diagnostic; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Reproducibility of Results; Vascular Endothelial Growth Factor A; Vitreous Body | 2016 |
Association of neovascular age-related macular degeneration with month and season of birth in Italy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Incidence; Italy; Macular Degeneration; Male; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Seasons; Treatment Outcome; Vascular Endothelial Growth Factor A | 2016 |
[Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Administration Schedule; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Middle Aged; Retreatment; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
[Treatment of neovascular age-related macular degeneration: an unresolved matter].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug Approval; Drug Costs; Europe; Humans; Macular Degeneration; National Health Programs; New Zealand; Porphyrins; Ranibizumab; Spain; State Medicine; United States; Verteporfin | 2008 |
Predictors of anti-VEGF-associated retinal pigment epithelial tear using FA and OCT analysis.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Macular Degeneration; Male; Predictive Value of Tests; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Pigment Epithelium; Retinal Vessels; Retrospective Studies; Risk Assessment; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2008 |
Pegaptanib sodium for occult choroidal neovascularization in neovascular age-related macular degeneration: a prospective case series.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Compassionate Use Trials; Female; Fluorescein Angiography; Humans; Macular Degeneration; Male; Middle Aged; Outcome Assessment, Health Care; Prospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |
Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Blindness; Computer Simulation; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Humans; Laser Therapy; Macular Degeneration; Models, Economic; Photosensitizing Agents; Population Surveillance; Porphyrins; Ranibizumab; Treatment Outcome; Verteporfin; Visual Acuity | 2008 |
[Evolving intravitreous injection technique].
Topics: Adrenal Cortex Hormones; Antibiotic Prophylaxis; Aptamers, Nucleotide; Comorbidity; Contraindications; Drug Hypersensitivity; Eye Infections; Humans; Informed Consent; Injections; Macular Degeneration; Monitoring, Physiologic; Mydriatics; Practice Guidelines as Topic; Pupil; Retinal Artery Occlusion; Tonometry, Ocular; Unnecessary Procedures; Vitreous Body; Vitreous Hemorrhage | 2008 |
Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Disease Models, Animal; Dose-Response Relationship, Drug; Fluorescein Angiography; Injections; Light Coagulation; Macular Degeneration; Ranibizumab; Rats; Rats, Inbred BN; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
Safety monitoring with ocular anti-vascular endothelial growth factor therapies.
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Humans; Macular Degeneration; Macular Edema; Vascular Endothelial Growth Factors | 2008 |
Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Guidelines as Topic; Humans; Macular Degeneration; Ophthalmology; Periodicals as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Publishing; Quality Control; Randomized Controlled Trials as Topic; Ranibizumab; Verteporfin | 2009 |
Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Humans; Injections; Insurance, Health, Reimbursement; Macular Degeneration; Markov Chains; Middle Aged; Photochemotherapy; Quality of Life; Ranibizumab; Reproducibility of Results; Spain; Visual Acuity | 2008 |
Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Humans; Immunologic Factors; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Pigment Epithelium of Eye; Ranibizumab; Retinal Detachment; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Visual Acuity | 2009 |
New paradigms in the treatment of wet AMD: the impact of anti-VEGF therapy.
Topics: Ambulatory Care; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Critical Pathways; Early Diagnosis; England; Humans; Macular Degeneration; Physical Examination; Practice Guidelines as Topic; Ranibizumab; Referral and Consultation; Vascular Endothelial Growth Factor A | 2009 |
Endophthalmitis after anti-VEGF injections.
Topics: Angiogenesis Inhibitors; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cohort Studies; Drug Therapy, Combination; Endophthalmitis; Humans; Injections; Macular Degeneration; Ranibizumab; Risk Factors; Vascular Endothelial Growth Factor A; Vitreous Body | 2009 |
Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Costs and Cost Analysis; Health Care Costs; Health Services Research; Humans; Macular Degeneration; Markov Chains; Quality-Adjusted Life Years; Ranibizumab; Spain; Visual Acuity | 2010 |
[Application of aptamers to medicine: pharmacological profile and results of clinical trials on pegaptanib sodium (Macugen) for age-related macular degeneration].
Topics: Animals; Aptamers, Nucleotide; Humans; Macular Degeneration; Mice; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2009 |
Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies.
Topics: Adverse Drug Reaction Reporting Systems; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Databases, Factual; Drug Administration Routes; Humans; Macular Degeneration; Medical Records Systems, Computerized; Meta-Analysis as Topic; Product Surveillance, Postmarketing; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Registries; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Intravitreal pegaptanib sodium for choroidal neovascularisation secondary to age-related macular degeneration: Pan-European experience.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Cohort Studies; Humans; Intravitreal Injections; Macular Degeneration; Retrospective Studies; Vascular Endothelial Growth Factors; Visual Acuity | 2010 |
[Clinical experience with pegaptanib in the treatment of age-related macular degeneration (AMD)].
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Female; Fluorescein Angiography; Humans; Injections; Intraocular Pressure; Macular Degeneration; Male; Retinal Neovascularization; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
A cost-effectiveness analysis of three treatments for age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Humans; Injections; Macular Degeneration; Models, Economic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quality of Life; Quality-Adjusted Life Years; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity; Vitreous Body | 2010 |
Re: Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Humans; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Ranibizumab; Vascular Endothelial Growth Factor A; Verteporfin | 2010 |
Newly diagnosed exudative age-related macular degeneration treated with pegaptanib sodium monotherapy in US community-based practices: medical chart review study.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Choroidal Neovascularization; Community Medicine; Drug Administration Schedule; Exudates and Transudates; Female; Fovea Centralis; Humans; Injections, Intraocular; Macular Degeneration; Male; Medical Records; Middle Aged; Professional Practice; Retrospective Studies; Treatment Outcome; United States; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
Ranibizumab vs. pegaptanib: a cost-effectiveness study?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Cost-Benefit Analysis; Costs and Cost Analysis; Health Care Costs; Health Services Research; Humans; Macular Degeneration; Quality-Adjusted Life Years; Ranibizumab; Visual Acuity | 2010 |
[Retinal angiomatous proliferation with associated pigment epithelium detachment: anti-VEGF therapy].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Humans; Indocyanine Green; Intravitreal Injections; Macular Degeneration; Male; Ophthalmoscopes; Ranibizumab; Retina; Retinal Detachment; Retinal Neovascularization; Retrospective Studies; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
Antivascular endothelial growth factors in age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Injections, Intraocular; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2010 |
Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Fluorescein Angiography; Follow-Up Studies; Fovea Centralis; Glucocorticoids; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Prognosis; Retreatment; Retrospective Studies; Tomography, Optical Coherence; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
[Exsudative age-related macular degeneration treatment results in patients registered in the nation-wide AMADEUS register].
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Czech Republic; Female; Humans; Macular Degeneration; Male; Middle Aged; Photochemotherapy; Porphyrins; Ranibizumab; Registries; Verteporfin; Visual Acuity | 2010 |
[Reimbursement of medical expenses of the exsudative age-related macular degeneration treatment from the public health insurance].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Czech Republic; Humans; Insurance, Health, Reimbursement; Macular Degeneration; Photochemotherapy; Porphyrins; Ranibizumab; Verteporfin | 2010 |
[Sodium pegaptanib and ranibizumab in the treatment of the retinal pigment layer ablation in a patient with age-related macular degeneration--a case report].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Degeneration; Middle Aged; Ranibizumab; Retinal Pigment Epithelium; Tomography, Optical Coherence; Visual Acuity | 2010 |
[The change of the anti-VEGF agent in the treatment of exceptionally active choroidal neovascular membrane in age-related macular degeneration].
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Drug Substitution; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Degeneration; Male; Ranibizumab; Tomography, Optical Coherence; Vascular Endothelial Growth Factors | 2010 |
Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Aptamers, Nucleotide; Bevacizumab; Female; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Ranibizumab; Retrospective Studies; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity | 2010 |
Generalized pairwise comparisons of prioritized outcomes in the two-sample problem.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aptamers, Nucleotide; Colorectal Neoplasms; Disease-Free Survival; Fluorouracil; Humans; Leucovorin; Macular Degeneration; Organoplatinum Compounds; Oxaliplatin; Randomized Controlled Trials as Topic; Statistics as Topic; Treatment Outcome; Visual Acuity | 2010 |
The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthal
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cause of Death; Hemorrhage; Humans; Macular Degeneration; Myocardial Infarction; Photochemotherapy; Ranibizumab; Risk Factors; Stroke; Vascular Endothelial Growth Factor A | 2011 |
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy; Drug Utilization Review; Fee-for-Service Plans; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Middle Aged; Porphyrins; Ranibizumab; Retrospective Studies; United States; Vascular Endothelial Growth Factor A; Verteporfin | 2011 |
Retreatment criteria in anti-VEGF therapy of exudative AMD: critical analysis of present regimes and new morphological definition of "lesion activity".
Topics: Algorithms; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Decision Trees; European Union; Exudates and Transudates; Humans; Macular Degeneration; Practice Guidelines as Topic; Ranibizumab; Recurrence; Retreatment; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
[Results of an expert survey on VEGF inhibitors in ophthalmology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Data Collection; Diabetic Retinopathy; Germany; Humans; Interviews as Topic; Intravitreal Injections; Macular Degeneration; Ophthalmology; Practice Patterns, Physicians'; Ranibizumab; Vascular Endothelial Growth Factor A | 2011 |
Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Case-Control Studies; Endophthalmitis; Eye Diseases; Female; Follow-Up Studies; Health Services Research; Humans; Incidence; Intravitreal Injections; Macular Degeneration; Male; Medicare Part B; Proportional Hazards Models; Ranibizumab; Retinal Detachment; Retinal Perforations; Retrospective Studies; United States; Uveitis; Vascular Endothelial Growth Factor A; Vitreous Hemorrhage | 2011 |
Long-term visual outcome of pigment epithelial tears in association with anti-VEGF therapy of pigment epithelial detachment in AMD.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Female; Fluorescein Angiography; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Pigment Epithelium of Eye; Ranibizumab; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Vascular Endothelial Growth Factors; Visual Acuity | 2011 |
Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Aqueous Humor; Bacteria; Bevacizumab; Endophthalmitis; Eye Infections, Bacterial; Female; Humans; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Referral and Consultation; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2011 |
Sustained elevated intraocular pressures after intravitreal injection of bevacizumab, ranibizumab, and pegaptanib.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antihypertensive Agents; Aptamers, Nucleotide; Bevacizumab; Female; Filtering Surgery; Humans; Intraocular Pressure; Intravitreal Injections; Macular Degeneration; Male; Ocular Hypertension; Ranibizumab; Retreatment; Retrospective Studies; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity | 2011 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
[Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese].
Topics: Aged; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Asian People; Choroidal Neovascularization; Cost-Benefit Analysis; Humans; Macular Degeneration; Male; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A | 2011 |
[Intravitreal injections: AFSSAPS guide to good practice].
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical | 2012 |
Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece.
Topics: Aged; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cost-Benefit Analysis; Health Care Costs; Humans; Macular Degeneration; Markov Chains; Photochemotherapy; Porphyrins; Quality-Adjusted Life Years; Ranibizumab; Verteporfin | 2012 |
Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Disease Models, Animal; Electroretinography; Immunohistochemistry; Intravitreal Injections; Macular Degeneration; Rabbits; Ranibizumab; Retina; Vascular Endothelial Growth Factor A | 2012 |
[The effect comparison of ranibizumab and sodium pegaptanib on the retinal pigment epithelium ablation size in the treatment of age-related macular degeneration].
Topics: Aged; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Female; Humans; Macular Degeneration; Male; Ranibizumab; Retinal Pigment Epithelium; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2012 |
Effects of treatment change in patients with neovascular age-related macular degeneration; results from the Czech National Registry.
Topics: Aged; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Czech Republic; Female; Humans; Macular Degeneration; Male; Ranibizumab; Registries; Retrospective Studies; Treatment Failure | 2012 |
Pegaptanib sodium.
Topics: Aptamers, Nucleotide; Double-Blind Method; Humans; Macular Degeneration; Oligonucleotides; Randomized Controlled Trials as Topic; Treatment Outcome; Vascular Endothelial Growth Factor A | 2005 |
New treatments for age-related macular degeneration.
Topics: Aptamers, Nucleotide; Dietary Supplements; Humans; Laser Coagulation; Macular Degeneration; Oligonucleotides; Ophthalmologic Surgical Procedures; Photochemotherapy; Pregnadienediols | 2005 |
Aptamers: slowing progression of AMD.
Topics: Age Factors; Aptamers, Nucleotide; Disease Progression; Humans; Macular Degeneration; Oligonucleotides; United States; Vision, Ocular | 2005 |
Pegaptanib and age-related macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Dose-Response Relationship, Drug; Humans; Injections; Macular Degeneration; Oligonucleotides; Vitreous Body | 2005 |
New drug treats form of age-related macular degeneration. Macugen inhibits progression of wet AMD and also may restore some vision.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Humans; Macular Degeneration; Oligonucleotides | 2005 |
Pegaptanib sodium (Macugen) for macular degeneration.
Topics: Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Vision Disorders; Vitreous Body | 2005 |
[Antiangiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Eye Proteins; Humans; Macular Degeneration; Nerve Growth Factors; Photochemotherapy; Ranibizumab; Serpins; Vascular Endothelial Growth Factor A | 2005 |
[Antiangiogenesis therapy of age-related macular degeneration].
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Humans; Injections; Macular Degeneration; Oligonucleotides; Vascular Endothelial Growth Factors; Vitreous Body | 2005 |
A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.
Topics: Aptamers, Nucleotide; Binding Sites; Binding, Competitive; Cells, Cultured; Dimerization; Endothelium, Vascular; Heparin; Humans; Macular Degeneration; Magnetic Resonance Spectroscopy; Models, Molecular; Neovascularization, Pathologic; Pichia; Polyethylene Glycols; Protein Binding; Protein Conformation; Protein Isoforms; Protein Structure, Secondary; Protein Structure, Tertiary; Pyrimidines; RNA; Signal Transduction; Thermodynamics; Vascular Endothelial Growth Factor A | 2005 |
Short-term intraocular pressure trends following intravitreal pegaptanib (Macugen) injection.
Topics: Aptamers, Nucleotide; Humans; Injections; Intraocular Pressure; Macular Degeneration; Retrospective Studies; Tonometry, Ocular; Vitreous Body | 2006 |
Age-related macular degeneration: options for earlier detection and improved treatment.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Humans; Hypertension; Low-Level Light Therapy; Macular Degeneration; Risk Factors; Smoking; Visual Acuity; Vitamins | 2006 |
New treatments for AMD.
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Vascular Endothelial Growth Factor A | 2006 |
New perspectives on the treatment of age-related macular degeneration.
Topics: Age Factors; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Combined Modality Therapy; Genetic Therapy; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy | 2005 |
Pegaptanib for wet macular degeneration.
Topics: Age Factors; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Humans; Light Coagulation; Macular Degeneration; Molecular Structure; Photochemotherapy; Ranibizumab; Vascular Endothelial Growth Factor A; Vitamins | 2005 |
New drugs 06, part I.
Topics: Acamprosate; Adenine Nucleotides; Alcohol Deterrents; Amyloid; Analgesics, Non-Narcotic; Anti-HIV Agents; Antifungal Agents; Antineoplastic Agents; Aptamers, Nucleotide; Arabinonucleosides; Azabicyclo Compounds; Benzofurans; Clofarabine; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Echinocandins; Exenatide; Fibroblast Growth Factor 7; Guanine; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lipopeptides; Lipoproteins; Macular Degeneration; Micafungin; omega-Conotoxins; Patient Education as Topic; Peptides; Peptides, Cyclic; Piperazines; Pyrrolidines; Quinuclidines; Solifenacin Succinate; Stomatitis; Taurine; Tetrahydroisoquinolines; Urinary Incontinence; Venoms | 2006 |
Six-week outcomes after pegaptanib.
Topics: Aptamers, Nucleotide; Humans; Macular Degeneration; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitreous Body | 2006 |
Retinal pigment epithelial tear following intravitreal pegaptanib sodium.
Topics: Aged; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Indocyanine Green; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Retinal Detachment; Retinal Perforations; Tomography, Optical Coherence; Visual Acuity | 2006 |
[Comments on current therapeutic possibilities for neovascular age-related macula degeneration].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Germany; Glucocorticoids; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Porphyrins; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pregnadienediols; Ranibizumab; Triamcinolone; Verteporfin | 2006 |
A 76-year-old man with macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Antioxidants; Aptamers, Nucleotide; Humans; Laser Coagulation; Macular Degeneration; Male; Risk Factors; Vascular Endothelial Growth Factor A | 2006 |
Retinal pigment epithelial tears after pegaptanib injection for exudative age-related macular degeneration.
Topics: Aged; Aptamers, Nucleotide; Exudates and Transudates; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Pigment Epithelium of Eye; Retinal Perforations; Rupture | 2006 |
Macular degeneration. Advances in treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antioxidants; Aptamers, Nucleotide; Glucocorticoids; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy; Pregnadienediols; Ranibizumab; Triamcinolone | 2006 |
[Medical and legal issues related to the drugs currently used in the treatment of Age-Related Macular Degeneration (ARMD)].
Topics: Aptamers, Nucleotide; Drug Utilization; Humans; Macular Degeneration; Photosensitizing Agents; Porphyrins; Spain; Triamcinolone Acetonide; Verteporfin | 2006 |
Readers' responses to "the cost of marginal medicine is too high".
Topics: Aptamers, Nucleotide; Health Care Costs; Humans; Macular Degeneration; Medicare | 2006 |
Evolving European guidance on the medical management of neovascular age related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Evidence-Based Medicine; Humans; Macular Degeneration; Photochemotherapy; Pregnadienediols; Ranibizumab; Treatment Outcome; Triamcinolone Acetonide | 2006 |
Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A | 2006 |
Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration.
Topics: Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Disease Progression; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Middle Aged; Vascular Endothelial Growth Factor A; Vitreous Body | 2006 |
New treatments for age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Light Coagulation; Macular Degeneration; Photochemotherapy; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
[Age-related macular degeneration: therapeutic hopes].
Topics: Age of Onset; Aged; Aged, 80 and over; Aging; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Double-Blind Method; Female; Genetic Predisposition to Disease; Humans; Macular Degeneration; Male; Middle Aged; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
A value-based medicine comparison of interventions for subfoveal neovascular macular degeneration.
Topics: Aptamers, Nucleotide; Choroidal Neovascularization; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; Economics, Medical; Evidence-Based Medicine; Fovea Centralis; Health Care Costs; Humans; Laser Coagulation; Macular Degeneration; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quality of Life; Quality-Adjusted Life Years; Verteporfin; Visual Acuity | 2007 |
Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma.
Topics: Aged; Antihypertensive Agents; Aptamers, Nucleotide; Chronic Disease; Glaucoma, Open-Angle; Humans; Injections; Intraocular Pressure; Macular Degeneration; Retrospective Studies; Time Factors; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
New outlook for age-related macular degeneration.
Topics: Aged; Aging; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Fluorescein Angiography; Humans; Light Coagulation; Macular Degeneration; Nursing Assessment; Patient Education as Topic; Photochemotherapy; Ranibizumab; Tomography, Optical Coherence | 2007 |
[A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Drug Costs; Germany; Humans; Macular Degeneration; Ranibizumab; Treatment Outcome | 2007 |
Quantitative comparison of optical coherence tomography after pegaptanib or bevacizumab in neovascular age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Female; Humans; Injections; Macular Degeneration; Male; Retina; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
[Position of the Retinological Society, the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany on the current therapeutic possibilities for neovascular age-related macular degeneration].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Macular Degeneration; Ophthalmology; Photochemotherapy; Porphyrins; Pregnadienediols; Ranibizumab; Societies, Medical; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Verteporfin | 2007 |
Macular degeneration, patients' groups, and pharma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost-Benefit Analysis; Humans; Macular Degeneration; National Health Programs; Patient Rights; Public Opinion; Ranibizumab; United Kingdom | 2007 |
Clinical update: new treatments for age-related macular degeneration.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Coronary Disease; Half-Life; Humans; Macular Degeneration; Randomized Controlled Trials as Topic; Ranibizumab; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Treatment of exudative age-related macular degeneration: many factors to consider.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost of Illness; Disease Models, Animal; Drug Costs; Humans; Injections; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A; Vitreous Body | 2007 |
Safety of intravitreal injections in patients receiving warfarin anticoagulation.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Anticoagulants; Aptamers, Nucleotide; Aspirin; Celecoxib; Choroidal Neovascularization; Drug Therapy, Combination; Eye Hemorrhage; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Pyrazoles; Retrospective Studies; Sulfonamides; Vascular Endothelial Growth Factor A; Vitreous Body; Warfarin | 2007 |
Cost effectiveness of pegaptanib for the treatment of age-related macular degeneration in the UK.
Topics: Age Factors; Aged; Aged, 80 and over; Aptamers, Nucleotide; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Humans; Macular Degeneration; Male; Markov Chains; Middle Aged; Models, Statistical; Quality-Adjusted Life Years; Reproducibility of Results; Sex Factors; Treatment Outcome; United Kingdom; Vascular Endothelial Growth Factor A; Visual Acuity | 2007 |
Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Retrospective Studies; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
RPE tears after pegaptanib treatment in age-related macular degeneration.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Female; Fluorescein Angiography; Humans; Injections; Macular Degeneration; Male; Pigment Epithelium of Eye; Postoperative Complications; Retinal Perforations; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
Multifocal electroretinography in patients with exudative amd and intravitreal treatment with pegaptanib sodium.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Aptamers, Nucleotide; Choroidal Neovascularization; Electroretinography; Exudates and Transudates; Female; Humans; Injections; Macular Degeneration; Male; Middle Aged; Retina; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2007 |
New treatments for age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Dose-Response Relationship, Drug; Humans; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factor A | 2007 |
New treatments for age-related macular degeneration.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Rabbits; Ranibizumab; Reference Values | 2007 |
Drug delivery to the back of the eye.
Topics: Antiviral Agents; Aptamers, Nucleotide; Clinical Trials, Phase III as Topic; Drug Administration Routes; Drug Delivery Systems; Eye Diseases; Glaucoma; Humans; Injections; Macular Degeneration; Nanoparticles; Oligonucleotides, Antisense; Ophthalmic Solutions; Retinal Diseases; Thionucleotides; Vascular Endothelial Growth Factor A | 2007 |
[New therapeutic aspects in age-related macular degeneration].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Clinical Trials, Phase III as Topic; Disease Progression; Forecasting; Humans; Macular Degeneration; Middle Aged; Multicenter Studies as Topic; Photochemotherapy; Photosensitizing Agents; Porphyrins; Randomized Controlled Trials as Topic; Ranibizumab; Risk Factors; Smoking; Smoking Cessation; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity | 2007 |
Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Canada; Cost-Benefit Analysis; Female; Fovea Centralis; Humans; Laser Coagulation; Macular Degeneration; Male; Models, Econometric; Photochemotherapy; Photosensitizing Agents; Porphyrins; Quality-Adjusted Life Years; Vascular Endothelial Growth Factor A; Verteporfin; Visual Acuity | 2007 |
Intraocular pressure effects of pegaptanib (macugen) injections in patients with and without glaucoma.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Chronic Disease; Glaucoma, Open-Angle; Humans; Injections; Intraocular Pressure; Macular Degeneration; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Vitreous Body | 2008 |
[The current state and issues of medical treatment for age-related macular degeneration].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Degeneration; Ranibizumab; Vascular Endothelial Growth Factors | 2008 |
AMD: out of sight out of mind.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Cost-Benefit Analysis; Drug Approval; Drug Costs; Drug Utilization; Geriatric Nursing; Health Promotion; Humans; Macular Degeneration; Nurse's Role; Ophthalmology; Practice Guidelines as Topic; Practice Patterns, Physicians'; Ranibizumab; Risk Factors; State Medicine; Treatment Outcome; United Kingdom | 2007 |
Incidence of ocular hemorrhages in anticoagulated patients receiving repeated intravitreal injections.
Topics: Angiogenesis Inhibitors; Anticoagulants; Aptamers, Nucleotide; Aspirin; Choroidal Neovascularization; Drug Therapy, Combination; Eye Hemorrhage; Humans; Incidence; Injections; Macular Degeneration; Risk Factors; Vascular Endothelial Growth Factor A; Vitreous Body; Warfarin | 2008 |
[Introduction to the topic: anti-VEGF therapy in the management of AMD].
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Choroidal Neovascularization; Endophthalmitis; Humans; Injections; Macular Degeneration; Postoperative Care; Ranibizumab; Time Factors; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Correspondence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Choroidal Neovascularization; Humans; Injections; Macular Degeneration; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2008 |
Early response of retinal angiomatous proliferation treated with intravitreal pegaptanib: a retrospective review.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiomatosis; Aptamers, Nucleotide; Drug Evaluation; Female; Follow-Up Studies; Humans; Injections, Intraocular; Macular Degeneration; Male; Middle Aged; Retinal Diseases; Retrospective Studies; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |